MRC2 Promotes Proliferation and Inhibits Apoptosis of Diabetic Nephropathy

Lanlan Li1, Xin Chen1, Henglu Zhang1

  • 1Department of Endocrinology and Metabolism, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, China.

Insights

Diabetic nephropathy (DN) involves kidney damage. Researchers found that blocking Type 2 mannose receptor C (MRC2) reduced kidney cell proliferation and increased apoptosis, suggesting MRC2 as a potential therapeutic target for DN.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Endocrinology

Background:

  • Diabetic nephropathy (DN) is a major complication of diabetes, leading to end-stage renal disease.
  • Type 2 mannose receptor C (MRC2) is implicated in cell migration and invasion pathways.
  • MRC2 expression is elevated in DN kidney tissues, but its specific role remains undefined.

Purpose of the Study:

  • To investigate the functional role of MRC2 in diabetic nephropathy.
  • To determine if MRC2 influences the proliferation and apoptosis of mouse mesangial cells (MMCs).

Main Methods:

  • Complementary DNA (cDNA) chip screening identified upregulated MRC2 in DN kidneys.
  • Quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting validated MRC2 expression.
  • Small interfering RNAs (siRNAs) were used to knockdown MRC2 in MMCs.
  • Cell Counting Kit-8 assay, western blotting, and flow cytometry assessed MMC proliferation and apoptosis.

Main Results:

  • MRC2 knockdown significantly inhibited proliferation in mouse mesangial cells.
  • Reduced MRC2 expression induced apoptosis in MMCs.
  • Validated upregulation of MRC2 in DN models.

Conclusions:

  • MRC2 plays a critical role in promoting cell proliferation and inhibiting apoptosis in the context of diabetic nephropathy.
  • MRC2 represents a potential molecular marker and therapeutic target for DN treatment.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K